Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition

NCT03083691 is registered in ClinicalTrials.gov with Lung Cancer Group Cologne as lead sponsor.

NCT NCT03083691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03083691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition
Lead sponsor
Lung Cancer Group Cologne
Phase
Phase 2
Overall status
Completed
Start date
April 13, 2017
Completion date
November 20, 2023
Enrollment
90 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, carcinoma, small cell lung